News &amp; Updates

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and liraglutide, improves histologic outcomes in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) without compromising safety, reports a Singapore study.

Age, comorbid SUDs modify mental health risks linked to cannabis use disorder

Mental health risks associated with cannabis use disorder (CUD) differ by age and comorbid substance use disorders (SUDs), suggests a study.

ROSELLA final analysis: 4-month OS increase with relacorilant in platinum-resistant ovarian cancer

The final overall survival (OS) analysis of the phase III ROSELLA clinical trial reports an increase of 4.1 months in median OS in patients with platinum-resistant ovarian cancer who received relacorilant in addition to nab-paclitaxel vs those who received nab-paclitaxel alone.

23 Apr 2026

MM780G system effectively maintains glycaemic control on no-bolus days

A real-world analysis shows effective glycaemic control with the MiniMed 780G (MM780G) system—an advanced automated insulin delivery (AID) system with bolus autocorrection every 5 min—in users on no-bolus days, with more users achieving glycaemic goals when the recommended optimal settings (ROS) were used.

Deuruxolitinib improves scalp hair regrowth in patients with severe AA

Treatment with deuruxolitinib, an oral Janus kinase 1/2 inhibitor, resulted in significant hair regrowth on the scalp for 24 weeks among patients with severe alopecia areata (AA), according to the two phase III THRIVE-AA1 and -AA2 trials presented at AAD 2026.

23 Apr 2026

Mobile tech helps lower alcohol intake among heavy drinkers

Mobile technologies that track blood alcohol concentration (BAC) show potential in reducing alcohol intake among individuals with heavy drinking, reveals a study.

Mediterranean diet may prevent asthma onset in adults

22 Apr 2026 by

Adherence to a Mediterranean diet (MedDiet) appears to reduce the incidence of adult-onset asthma, suggests a recent study, noting that causality cannot be inferred due to its observational design.

22 Apr 2026

Approach bias modification offers no added benefit to smoking cessation treatment

Cognitive-behavioural smoking cessation treatment (treatment as usual [TAU]) coupled with approach bias modification (ApBM) does not appear to be any better than TAU plus sham training or TAU only, a recent study has shown.

Health supplements: Help or hype?

22 Apr 2026 by

A review of 19 meta-analyses shows mixed results on the effects of multivitamin and mineral (MVM) supplementation on health outcomes.

Rilzabrutinib shows potential in patients with uncontrolled asthma

BTK inhibition with rilzabrutinib does not appear to significantly decrease the incidence of loss-of-asthma-control (LOAC) event compared with placebo in patients with moderate-to-severe asthma with uncontrolled symptoms, according to a phase II study. However, the investigational drug has been associated with meaningful symptom improvements over time, despite withdrawal of background therapy.